GREY:ATBPF - Post by User
Comment by
Jefferam1on Jul 11, 2018 9:03am
240 Views
Post# 28298452
RE:zachs target price
RE:zachs target priceI'm not one to put much weigth on Zacks as I'm not convinced they have the track record to prove how accurate their valuation are.
But let's be intertained for a second.
If Zacks sayd 1.80 valuation, that is strickly based on ATB-346 they are not looking at our other pipeline drugs. (nor citagenix which is basically a write off anyway).
The market size for our next 2 pipeline drugs combined is comparable to ATB-346.
Since this compound is basically win or bust - It's probably fairly consistent in the pipeline.
If ATB-346 takes Antibe to 1.80, it should be reasonably safe to say our next two pipeline durgs should add an additiona 1.80 to price makeing ATE valuation about 3.60.
I myself find that's a little lower then I'd expect, I think we are in the $4-$8 range (1-2 Billion market cap). But all the same, we are talking making roughly 10x our money in the next 1-3 years (pending on how quick some of this unravels.
I'm looking forward to that.
Just a waiting game at this point.